

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Prophylactic and Therapeutic Antibodies (Q3)

Scientific Organizers: Margaret Karow and Neil Stahl

Supported by the Directors' Fund

Biology of B Cell Responses (Q4)

Scientific Organizers: Hedda Wardemann, Michael G. McHeyzer-Williams and Michel C. Nussenzweig

February 9-14, 2014 • Keystone Resort • Keystone, Colorado, USA

Supported by the Directors' Fund

Abstract & Scholarship Deadline: October 9, 2013 / Abstract Deadline: November 14, 2013 / Discounted Registration Deadline: December 10, 2013

SUNDAY, FEBRUARY 9

MONDAY, FEBRUARY 10

Keynote Address (Q3)

Joseph Miletich, Amgen, USA

Antibody Therapeutic Indications: Expanding beyond Cancer and Inflammatory Diseases

Keynote Address (Q4)

Jason G. Cyster, HHMI/University of California, San Francisco, USA
Lymphocyte Migration

Novel Antibody Therapy for Pain (Q3)

Mark Brown, Pfizer, USA

Overview of Analgesic Efficacy and Safety of Tanezumab, a Monoclonal Antibody Targeting Nerve Growth Factor for Treatment of Chronic Pain

John A. Latham, Alder Biopharmaceuticals, USA

The Discovery and Development of an Anti-CGRP Antibody ALD403 for the Treatment of Migraine

Stephen P. Squinto, Alexion Pharmaceuticals, Inc., USA

Treatment of Hemolytic Diseases with Inhibitors of the Complement Cascade

Short Talk(s) Chosen from Abstracts

Programming B Cell Physiology (Q4)

Barry P. Sleckman, Washington University School of Medicine, USA
Pathways of Normal and Aberrant RAG Double Strand Break Repair in Developing B Cells

Cornelis Murre, University of California, San Diego, USA

Global analysis of long-range genomic interactions that orchestrate B cell fate

Hassan Jumaa, Max Planck Institute for Immunobiology, Germany
Pre B Cell Development

Short Talk(s) Chosen from Abstracts

Workshop 1: Crossing the Blood Brain Barrier (Q3)

Short Talks Chosen from Abstracts

Workshop 1 (Q4)

Short Talks Chosen from Abstracts

Treating Chronic Diseases of Metabolism with Antibody-Based Therapeutics (Q3)

Neil Stahl, Regeneron Pharmaceuticals, USA

Reduction of LDL with the Inhibition of PCSK9 by REGN727

Peter Libby, Brigham and Women's Hospital, USA

Inflammation and Atherosclerosis: A Rationale for Antibody Treatment

David J. Glass†, Novartis Institutes for Biomedical Research, USA

Building Stronger Bodies through Antibody Treatment of Skeletal Muscle

Short Talk Chosen from Abstracts

Self-Tolerance and Autoimmunity (Q4)

Christopher C. Goodnow, Australian National University, Australia
B Cell Self-Tolerance

Ann Marshak-Rothstein, University of Massachusetts Medical School, USA

(De-)Regulation of B Cell Activation

Roberta Pelanda, National Jewish Health, USA

Positive and Negative Selection of Primary B Cells

Short Talk Chosen from Abstracts

Poster Session 1

TUESDAY, FEBRUARY 11

Tailoring Therapeutics to Meet the Demands of Prophylactic and Long Term Therapy (Q3)

Herren Wu, MedImmune, USA

Engineering Biosuperiors

Javier Chaparro-Riggers, Rinat/Pfizer Inc., USA

Engineering pH-Sensitive Binding to a PCSK9 Antibody for Improved Pharmacokinetics and Efficacy

Tomoyuki Igawa, Chugai Pharmaceutical, Japan

Bispecific IgG Antibody Against FIXa and FX (ACE910) for the Treatment of Hemophilia A

Short Talk(s) Chosen from Abstracts

Initiating and Regulating B Cell Responses (Q4)

Facundo D. Batista, Cancer Research UK, London Research Institute, UK

Dynamic Imaging of Lymphocyte Activation - From Single Molecule to Living Tissue

Susan K. Pierce, NIAID, National Institutes of Health, USA

B Cell Responses in Malaria

Tomohiro Kurosaki, WPI Immunology Frontier Research Center, Osaka University, Japan

B Cell Differentiation

Jeffrey V. Ravetch, Rockefeller University, USA

Regulating B Cell Activation

Short Talk(s) Chosen from Abstracts

Workshop 2 (Q4)

Short Talks Chosen from Abstracts

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Prophylactic and Therapeutic Antibodies (Q3)

Scientific Organizers: Margaret Karow and Neil Stahl

Supported by the Directors' Fund

Biology of B Cell Responses (Q4)

Scientific Organizers: Hedda Wardemann, Michael G. McHeyzer-Williams and Michel C. Nussenzweig

February 9-14, 2014 • Keystone Resort • Keystone, Colorado, USA

Supported by the Directors' Fund

Abstract & Scholarship Deadline: October 9, 2013 / Abstract Deadline: November 14, 2013 / Discounted Registration Deadline: December 10, 2013

Workshop 3 (Q4)

Short Talks Chosen from Abstracts

Overcoming Challenging Indications for Antibody Therapeutics (Q3)

Bruce Roberts, Genzyme Corporation, USA

From Campath to Lemtrada: MOA and Clinical Path for the Treatment of Multiple Sclerosis

Andreas Grauer, Amgen, USA

Targeting Osteoporosis: Increasing Bone Strength with Antibodies Against RANK-L and Sclerostin

Iain Chessell[†], MedImmune, UK

Antibody Therapeutics in Neuroscience

Short Talk Chosen from Abstracts

B Cell Responses to Foreign Antigens (Q4)

Antonio Lanzavecchia, Institute for Research in Biomedicine, Switzerland

B Cell Memory to Infection

Patrick C. Wilson, University of Chicago, USA

The Human B Cell Response to Viral Infection

Hedda Wardemann, Max-Planck Institute for Infection Biology, Germany

Talk Title to be Determined

Short Talk Chosen from Abstracts

Poster Session 2

WEDNESDAY, FEBRUARY 12

Prophylaxis vs. Therapeutic Treatment of Infectious Disease (Q3)

Jaap Goudsmit[†], Crucell Holland B.V., Netherlands

Vaccines vs. Antibody Therapy for the Treatment of Infectious Disease

Jeanine Wiener-Kronish, Massachusetts General Hospital, USA

Treatment of Pseudomonas aeruginosa Infection with Antibody Therapeutics

Deborah C. Molrine, University of Massachusetts Medical School, USA

Antibody Mixtures: Treating Clostridium with an Antibody Combination

JoAnn Suzich, MedImmune, USA

A Novel Multi-Mechanistic Monoclonal Antibody for Treating P. aeruginosa Infections

Short Talk(s) Chosen from Abstracts

Regulating B Cell Immunity (Q4)

Marc K. Jenkins, University of Minnesota Medical School, USA

Origins of CD4+ Memory T Cells

Michael G. McHeyzer-Williams, The Scripps Research Institute, USA
Regulating B Cell Immunity

Carola G. Vinuesa, Australian National University, Australia

Selection of Memory B Cells

Shane Crotty, La Jolla Institute for Allergy and Immunology, USA

T Cell Help to B Cells: Differentiation and Function of Follicular Helper CD4 T Cells (T_{fh})

Short Talk(s) Chosen from Abstracts

Workshop 2: Smallerbody and Polyclonal Antibody Approaches (Q3)

Short Talks Chosen from Abstracts

Workshop 4 (Q4)

Short Talks Chosen from Abstracts

Workshop 5 (Q4)

Short Talks Chosen from Abstracts

In vivo Induction of Therapeutic Antibodies for Prophylactic Treatment of Disease (Q3)

Peter M. Palese, Mount Sinai School of Medicine, USA

The Next Generation of Anti-Influenza Antibody Inducing Vaccines

Daniel Zagury[†], Neovacs SA, France

Active and Passive Anticytokine Immune Therapies: Current Status and Development

Ronald G. Crystal, Weill Medical College of Cornell University, USA

Viral Vectors as Platforms for Anti-Addiction Vaccines

Ira Mellman, Genentech, Inc., USA

Antibody Mediated Antigen Delivery for Vaccine Antigens to Dendritic Cells

Germinal Center Biology (Q4)

David M. Tarlinton, Walter and Eliza Hall Institute of Medical Research, Australia

B Cell Responses

Mark J. Shlomchik, Yale University School of Medicine, USA

Germinal Center Selection and the Development of Memory B and Plasma Cells

Michel C. Nussenzweig, HHMI/Rockefeller University, USA

Germinal Center Biology

Short Talk Chosen from Abstracts

Poster Session 3

THURSDAY, FEBRUARY 13

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Prophylactic and Therapeutic Antibodies (Q3)

Scientific Organizers: Margaret Karow and Neil Stahl

Supported by the Directors' Fund

Biology of B Cell Responses (Q4)

Scientific Organizers: Hedda Wardemann, Michael G. McHeyzer-Williams and Michel C. Nussenzweig

February 9-14, 2014 • Keystone Resort • Keystone, Colorado, USA

Supported by the Directors' Fund

Abstract & Scholarship Deadline: October 9, 2013 / Abstract Deadline: November 14, 2013 / Discounted Registration Deadline: December 10, 2013

Generation of Diversity (Joint)

Max D. Cooper, Emory University, USA

Immune System Ontogeny and Phylogeny

David G. Schatz, Yale University School of Medicine, USA

Targeting of V(D)J Recombination and Somatic Hypermutation

Cristina Rada, MRC Laboratory of Molecular Biology, UK

Ig Gene Mutagenesis

Frederick W. Alt, Boston Children's Hospital, USA

Mechanisms of CSR and SHM

Short Talk Chosen from Abstracts

Workshop 3: Off-Target Activities of Antibodies (Q3)

Short Talks Chosen from Abstracts

Workshop 6 (Q4)

Short Talks Chosen from Abstracts

What We've Learned from Antibody Treatment of Inflammation (Q3)

Marc Feldmann, University of Oxford, UK

Antibody Therapy of Rheumatoid Arthritis: Getting Closer to a Cure

Thomas A. Waldmann, National Institutes of Health, USA

T-Cell Cytokine Receptors: Targets for Monoclonal Antibody Mediated

Treatment of Lymphoma and Autoimmune Diseases

Stephen T. Holgate, Southampton General Hospital, UK

Treating Asthma with Antibody Therapeutics

Short Talk Chosen from Abstracts

B Cell Cancer Biology (Q4)

Klaus Rajewsky[†], Max Delbrück Center for Molecular Medicine, Germany

B Cell Immune Regulation

Louis M. Staudt, NCI, National Institutes of Health, USA

Therapies Targeting Pathological Signaling in B Cell Lymphomas

Riccardo Dalla-Favera, Columbia University, USA

Human Germinal Center B Cell Tumors

Short Talk Chosen from Abstracts

FRIDAY, FEBRUARY 14